Pacira Biosciences Inc
NASDAQ:PCRX
Pacira Biosciences Inc
Net Income (Common)
Pacira Biosciences Inc
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Pacira Biosciences Inc
NASDAQ:PCRX
|
Net Income (Common)
$42m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Income (Common)
$38.5B
|
CAGR 3-Years
37%
|
CAGR 5-Years
21%
|
CAGR 10-Years
10%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Income (Common)
-$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pfizer Inc
NYSE:PFE
|
Net Income (Common)
-$309m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income (Common)
$2.3B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-7%
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income (Common)
$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
See Also
What is Pacira Biosciences Inc's Net Income (Common)?
Net Income (Common)
42m
USD
Based on the financial report for Dec 31, 2023, Pacira Biosciences Inc's Net Income (Common) amounts to 42m USD.
What is Pacira Biosciences Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-34%
Over the last year, the Net Income (Common) growth was 164%. The average annual Net Income (Common) growth rates for Pacira Biosciences Inc have been -34% over the past three years .